Program Agenda

5:00 pm  Registration

5:30 pm  Welcome and Introductions
Daniel A. Haber, MD, PhD
Director, Mass General Cancer Center
Henri A. Termeer
Former Chairman, President and CEO, Genzyme Corporation
Keith Flaherty, MD
Director, Henri and Belinda Termeer Center for Targeted Therapies, Mass General Cancer Center

Panel Discussion
Inside the Cancer Immunotherapy Revolution: How Does Immunotherapy Actually Work and Who Benefits From It?
Moderator
Nir Hacohen, MD
Director, Center for Cancer Immunology and Center for Cancer Research, Mass General Cancer Center

Panelists
Glenn Dranoff, MD
Global Head, Exploratory Immuno-Oncology
Novartis Institutes for BioMedical Research
Elizabeth M. Jaffee, MD
Deputy Director, The Sidney Kimmel Cancer Center, Johns Hopkins
David Kaufman, MD, PhD
Executive Director, Translational Immuno-Oncology Research, Merck Research Laboratories
Arlene H. Sharpe, MD, PhD
Co-Directory, Harvard Institute of Translational Immunology, Harvard Medical School

Directions to the Paul S. Russell MD Museum of Medical History and Innovation

Mass General Parking Garages  Parking will be validated (for up to 4 hours)

From the North or South
1. Via I-93 or U.S.-1 take the Storrow Drive exit
2. Take the Government Center exit (on left)
3. At second traffic light, take left onto Cambridge Street (follow signs to Downtown and Government Center)
4. Keep right at the fork, then continue straight.
5. Once underneath the T station overpass, take a slight left onto Cambridge Street.
6. At the first set of lights, take left into the main entrance of Massachusetts General Hospital. The entrance to the museum will be directly on your left.
7. Park in the Fruit Street Garage, Parkman Street Garage or Yawkey Center Garage.

From the West
1. Via the Massachusetts Turnpike, take Exit 18 towards Brighton/ Cambridge
2. Bear right after the toll booth (follow signs for Cambridge/ Somerville)
3. Turn right onto Storrow Drive eastbound to Downtown Boston
4. Take the Government Center exit
5. Proceed through traffic light onto Cambridge Street, towards Government Center
6. At the first set of lights, take left into the main entrance of Massachusetts General Hospital. The entrance to the museum will be directly on your left.
7. Park in the Fruit Street Garage, Parkman Street Garage or Yawkey Center Garage.

The Henri and Belinda Termeer Center for Targeted Therapies Presents a Roundtable Panel Discussion on
Inside the Cancer Immunotherapy Revolution: How Does Immunotherapy Actually Work and Who Benefits From It?

Tuesday, March 1, 2016  •  5:00 pm – 8:30 pm
The Paul S. Russell MD Museum of Medical History and Innovation
Massachusetts General Hospital
2 North Grove Street  •  Boston, MA 02114

Please respond by email to Elizabeth Sweeney at esweeney1@partners.org or by phone at 617-724-0958.
Panelists

Nir Hacohen, PhD  •  moderator
Dr. Hacohen is an immunologist and geneticist who develops and applies unbiased methods to understand the mammalian immune response. His group works on discovering the drivers and resistors of tumor immunity in humans; mechanisms by which the innate immune system senses normal cells, tumor cells, viruses and bacteria; analyzing the genetic basis for function and variation in the immune response across individuals; and developing personalized immunotherapies. He is also co-director of the Broad Institute Cell Circuits Program and the Center for Cell Circuits Consortium.

Glenn Dranoff, MD
Prior to his role as Global Head of Exploratory Immunology at Novartis, Dr. Dranoff served as Professor of Medicine at Dana-Farber Cancer Institute (DFCI) and Harvard Medical School, where work in his laboratory gave rise to multiple clinical protocols at the DFCI that have defined the biologic activity of several cancer immunotherapies in patients with solid or hematologic malignancies. These investigations have helped provide the foundation for the recent FDA approvals of the first therapeutic cancer vaccine and the first monoclonal antibody that blocks negative immune regulation.

Arlene H. Sharpe, MD, PhD
Dr. Sharpe is a leader in the field of T-cell costimulation, and investigates how costimulatory pathways regulate immune responses. Her laboratory has discovered and elucidated the functions of T cell costimulatory pathways, including the immunoinhibitory functions of the CTLA-4 and PD-1 pathways. Her laboratory currently focuses on the roles of T cell costimulatory pathways in regulating T-cell tolerance and effective antimicrobial and antitumor immunity, and is also involved in studies aimed at translating fundamental understanding of T cell costimulation into new therapies for autoimmune diseases and cancer.

David Kaufman, MD, PhD
Dr. Kaufman serves as the human/translational immunology lead for cancer immunotherapy programs at Merck Pharmaceuticals. He has had multiple roles in the pembrolizumab program, including oversight of translational through registrational clinical studies. Prior to joining Merck, he was a staff physician at Beth Israel Deaconess Medical Center and an Instructor in Medicine at Harvard Medical School, where his research focused on preclinical HIV vaccine development and mechanisms of vaccine-elicited mucosal immunity.

Hosts

Daniel A. Haber, MD, PhD
Director, Mass General Cancer Center
Dr. Haber is Director of the Mass General Cancer Center and the Isselbacher/Schwartz Professor of Oncology at Harvard Medical School. His laboratory focuses on cancer genetics and is broadly known for discoveries that have improved the treatment of cancers such as non-small cell lung cancer, breast cancer and Wilms tumor, as well as for innovation in cancer diagnostics.

Henri A. Termeer
Former Chairman, President and CEO, Genzyme Corporation
Mr. Termeer served as Chairman, President and Chief Executive Officer of Genzyme Corporation for nearly three decades. Under his leadership, Genzyme grew from a modest entrepreneurial venture into one of the world’s leading biotechnology companies. Mr. Termeer resigned from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi. He is a member of the board at both Mass General Hospital and Partners HealthCare.

Keith T. Flaherty, MD
Dr. Flaherty is Director of the Henri and Belinda Termeer Center for Targeted Therapies at the Mass General Cancer Center and Associate Professor of Medicine at Harvard Medical School. Dr. Flaherty’s research and clinical focus is therapies for melanoma, with a particular expertise in targeted therapies.

Arlene H. Sharpe, MD, PhD
Dr. Sharpe is a leader in the field of T-cell costimulation, and investigates how costimulatory pathways regulate immune responses. Her laboratory has discovered and elucidated the functions of T cell costimulatory pathways, including the immunoinhibitory functions of the CTLA-4 and PD-1 pathways. Her laboratory currently focuses on the roles of T cell costimulatory pathways in regulating T-cell tolerance and effective antimicrobial and antitumor immunity, and is also involved in studies aimed at translating fundamental understanding of T cell costimulation into new therapies for autoimmune diseases and cancer.

Glenn Dranoff, MD
Prior to his role as Global Head of Exploratory Immunology at Novartis, Dr. Dranoff served as Professor of Medicine at Dana-Farber Cancer Institute (DFCI) and Harvard Medical School, where work in his laboratory gave rise to multiple clinical protocols at the DFCI that have defined the biologic activity of several cancer immunotherapies in patients with solid or hematologic malignancies. These investigations have helped provide the foundation for the recent FDA approvals of the first therapeutic cancer vaccine and the first monoclonal antibody that blocks negative immune regulation.

David Kaufman, MD, PhD
Dr. Kaufman serves as the human/translational immunology lead for cancer immunotherapy programs at Merck Pharmaceuticals. He has had multiple roles in the pembrolizumab program, including oversight of translational through registrational clinical studies. Prior to joining Merck, he was a staff physician at Beth Israel Deaconess Medical Center and an Instructor in Medicine at Harvard Medical School, where his research focused on preclinical HIV vaccine development and mechanisms of vaccine-elicited mucosal immunity.